What’s the current market cap for Kamada stock?

Kamada (KMDA) has a market cap of $465M as of May 27, 2026.

What is the P/E ratio for Kamada stock?

The price to earnings (P/E) ratio for Kamada (KMDA) stock is 22.76 as of May 27, 2026.

Does Kamada stock pay dividends?

Yes, the Kamada (KMDA) stock pays dividends to shareholders. As of May 27, 2026, the dividend rate is $0.25 and the yield is 3.14%. Kamada has a payout ratio of 56.63% on a trailing twelve-month basis.

When is the next Kamada dividend payment date?

The next Kamada (KMDA) dividend payment date is unconfirmed.

What is the beta indicator for Kamada?

Kamada (KMDA) does not currently have a Beta indicator.

Buy Kamada stock | $KMDA Share Price

13:30

15:10

16:45

18:25

20:00

About Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Ticker

$KMDA

Sector

Health

Primary listing

NASDAQ

Employees

462

Headquarters

Rehovot, Israel

Website

www.kamada.com

Kamada Metrics

BasicAdvanced

$465m

22.76

$0.35

$0.25

3.14%

What the Analysts think about Kamada

Analyst ratings (Buy, Hold, Sell) for Kamada stock.

Bulls say / Bears say

Kamada posted record full-year 2025 results with total revenues of $180.5 million (up 12% year over year), adjusted EBITDA of $42.0 million (up 23% year over year), and net income of $20.2 million (up 40% year over year), driven by strong performance across its plasma-derived portfolio.

Management issued 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, signaling about 13% revenue growth and 23% adjusted EBITDA growth, and showing confidence in continued double-digit organic growth.

In March 2026, the FDA approved Kamada’s San Antonio plasma collection center—with up to 50,000 liters annual capacity and an expected $8 million–$10 million revenue boost—strengthening the company's vertical integration and future supply security.

Kamada’s Q4 2025 results missed expectations, with revenue of $44.68 million compared to the $45.42 million consensus and EPS of $0.06 versus $0.10, causing shares to fall about 2.5% and highlighting operational volatility.

First-quarter 2026 revenue increased only 3% year over year to $45.2 million, indicating sluggish growth momentum amid rising competition in plasma-derived therapies.

Operating cash outflow of $0.3 million in Q1 2026 reduced cash from $75.5 million to $73.1 million, which could limit financial flexibility if this trend continues.

Data summarised monthly by Lightyear AI. Last updated on 18 May 2026.

Kamada Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Kamada Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KMDA

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

First-quarter 2026 revenue increased only 3% year over year to $45.2 million, indicating sluggish growth momentum amid rising competition in plasma-derived therapies.

Operating cash outflow of $0.3 million in Q1 2026 reduced cash from $75.5 million to $73.1 million, which could limit financial flexibility if this trend continues.

Data summarised monthly by Lightyear AI. Last updated on 18 May 2026.